1 Adeno-associated virus 2 infection in children with non-A-E hepatitis

2	Antonia Ho ^{1*} , Richard Orton ^{1*} , Rachel Tayler ^{2*} , Patawee Asamaphan ^{1*} , Lily Tong ¹ ,
3	Katherine Smollett ¹ , Chris Davis ¹ , Maria Manali ¹ , Sarah E. McDonald ¹ , Louisa Pollock ² , Clair
4	Evans ³ , Jim McMenamin ⁴ , Kirsty Roy ⁴ , Kimberly Marsh ⁴ , Titus Divala ⁴ , Matt Holden ⁴ ,
5	Michael Lockhart ⁴ , David Yirrell ⁴ , Sandra Currie ⁴ , Samantha J. Shepherd ⁵ , Celia Jackson ⁵ ,
6	Rory Gunson ⁵ , Alasdair MacLean ⁵ , Neil McInnes ⁵ , Richard Battle ⁶ , Jill Hollenbach ⁷ , Paul
7	Henderson ⁸ , Meera Chand ⁹ , Melissa Shea Hamilton ¹⁰ , Diego Estrada-Rivadeneyra ¹⁰ , Michael
8	Levin ¹⁰ , DIAMONDS consortium, ISARIC4C Investigators, David L Robertson ^{1†} , Ana
9	Filipe ^{1†} , Brian Willett ^{1†} , Judith Breuer ^{11†} , Malcolm G Semple ^{12†} , David Turner ^{6†} , J Kenneth
10	Baillie ^{8†} , Emma C. Thomson ^{1,13†}
11	
12	1. Medical Research Council-University of Glasgow Centre for Virus Research,
13	Glasgow, UK
14	2. Department of Paediatrics, Royal Hospital for Children, Glasgow, UK
15	3. Department of Pathology, Queen Elizabeth University Hospital, Glasgow, UK
16	4. Public Health Scotland, Glasgow, UK
17	5. West of Scotland Specialist Virology Centre, Glasgow, UK
18	6. Histocompatibility and Immunogenetics (H&I) Laboratory, Scottish National Blood
19	Transfusion Service, Edinburgh Royal Infirmary, Edinburgh, UK
20	7. University of California, San Francisco, USA
21	8. University of Edinburgh, Edinburgh, UK
22	9. UK Health Security Agency, UK
23	10. Section of Paediatric Infectious Disease, Department of Infectious Disease, Imperial
24	College London, London, UK

25 11. University College London, London, UK NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 26 12. Pandemic Institute, University of Liverpool, Liverpool, UK
- 27 13. Department of Clinical Research, London School of Hygiene and Tropical Medicine,

28 London, UK

- 30 *These authors contributed equally to this work
- 31 [†]These authors contributed equally to this work

32 Summary paragraph

33

An outbreak of acute hepatitis of unknown aetiology in children was first reported in Scotland 34 in April 2022.¹ Cases aged <16 years have since been identified in 35 countries.² Here we 35 report a detailed investigation of 9 early cases and 58 control subjects. Using next-generation 36 37 sequencing and real-time PCR, adeno-associated virus 2 (AAV2), was detected in the plasma 38 of 9/9 and liver of 4/4 patients but in 0/13 sera/plasma of age-matched healthy controls, 0/12 39 children with adenovirus (HAdV) infection and normal liver function and 0/33 children 40 admitted to hospital with hepatitis of other aetiology. AAV2 typically requires a coinfecting 'helper' virus to replicate, usually HAdV or a herpesvirus. HAdV (species C and F) and human 41 42 herpesvirus 6B (HHV6B) were detected in 6/9 and 3/9 affected cases, including 3/4 and 2/4 liver biopsies, respectively. The class II HLA-DRB1*04:01 allele was identified in 8/9 cases 43 44 (89%), compared with a background frequency of 15.6% in Scottish blood donors, suggestive 45 of increased susceptibility in affected cases. Acute non-A-E paediatric hepatitis is associated 46 with the presence of AAV2 infection, which could represent a primary pathogen or a useful biomarker of recent HAdV or HHV6B infection. Population and mechanistic studies are 47 48 required to explore these findings further.

49

51 Main text

52

53 Hepatitis outbreak in Scottish children

54 In April 2022, a cluster of five young children presented with jaundiceⁱ and acute severe hepatitis of unknown aetiology were reported by several hospital sites in Scotland.¹ In 55 response, Public Health Scotland (PHS) convened a National Incident Management Team 56 (IMT), alongside the UK Health Security Agency (UK HSA) and academic partners 57 58 (ISARIC4C Investigators) to coordinate further investigations and the public health response. 59 As of 4 July 2022, 36 children aged 10 years and under with acute unexplained non-A to E hepatitis have been confirmed in Scotland, one of whom required liver transplantation (Figure 60 1a).³ Elsewhere in the UK, 186 confirmed cases have been reported and 14 children have 61 62 required liver transplantation.³ Globally, the World Health Organisation (WHO) has reported over 1010 probable cases fulfilling their case definition in 35 countries.² Clinical investigations 63 64 in Scotland excluded all expected causes of acute hepatitis including hepatitis A, B, C and E 65 viruses, HSV, CMV and EBV. Adenovirus (HAdV) was identified by PCR in 53.1% (17/32) of tested cases. Recent reports from the UK and the USA have also identified HAdV to be 66 present in the majority of cases in two cohorts of children⁴⁻⁶. A spike of HAdV infections in 67 Scotland predominantly affecting children <5 years also directly preceded the outbreak of 68 unexplained hepatitis (Figure 1b). SARS-CoV-2 PCR was positive in 16.7% (6/36 tested 69 70 cases).³ A rise in COVID-19 cases in the community preceded the spike in non-A-E hepatitis 71 by around two years (Figure 1c). Human herpesvirus 6 (HHV6A and HHV6B) infections were not detected at higher levels during 2021 or 2022 (Figure 1d). 72

- 73
- 74
- 75

76 Research investigation

To investigate the aetiology of the acute hepatitis cases, we recruited nine of the earliest 77 affected children who presented to hospital between 14 March and 4 April 2022 into the 78 79 International Severe Acute Respiratory and Emerging Infections Consortium (ISARIC) WHO 80 Clinical Characterisation Protocol UK (CCP-UK) [ISRCTN 66726260]⁷. Ethical approval was given by the South Central–Oxford C Research Ethics Committee in England (13/SC/0149), 81 82 the Scotland A Research Ethics Committee (20/SS/0028), and the WHO Ethics Review Committee (RPC571 and RPC572). Control samples were obtained from the Diagnosis and 83 84 Management of Febrile Illness using RNA Personalised Molecular Signature Diagnosis study 85 cohort (DIAMONDS; https://www.diamonds2020.eu). This study recruited children presenting with suspected infection or inflammation. Patients were recruited with the informed 86 written consent of parents or guardians. The DIAMONDS study was approved by the London 87 88 - Dulwich Research Ethics Committee (20/HRA/1714).

89

90 Control subjects were restricted to children recruited in the UK between January 2020 and 91 April 2022. Three comparison groups were identified: Group 1, sera from 13 age-matched healthy children (10 male, 3 female; age range 3-5 years); Group 2, 12 children (8 male, 4 92 93 female; age range 1-4 years) with PCR-confirmed HAdV infection and normal transaminases 94 (n=12); Group 3, 33 children (18 male, 15 female; age range 2-16 years) with raised 95 transaminases who were HAdV PCR negative. Within Group 3, 15 children required critical 96 care for ventilatory or cardiovascular support. There was no significant difference in age 97 between cases and healthy controls, but some control samples were sampled earlier than case samples (January 2020-April 2022 versus March-April 2022). Children with HAdV infection 98 99 with normal liver function were younger (median age 1.6 years; interquartile range (IQR) 1.1-100 3.3 years, p<0.001), and children with deranged liver function and no adenoviral infection were

101 older (median age 9.2 years; IQR 6.7-13.6 years, p=0.001), compared to cases.
102 (Supplementary Table 1).

103

104 Clinical presentation

The median age of case patients was 3.9 years (IQR: 3.4 to 5.1 years). Four of the nine children 105 106 were male, and all were of white ethnicity. All were admitted to hospital and met the PHS case definition for confirmed acute hepatitis, with a serum transaminase >500 IU/L (AST or ALT) 107 108 without any known cause, aged 10 years or under and presenting after 1st January 2022. The 109 majority of the children reported a preceding subacute history of abdominal pain, diarrhoea and vomiting, occurring between 1 to 11 weeks prior to acute hepatitis. None of the cases were 110 111 immunocompromised and none had received COVID-19 vaccination. All routine blood tests 112 for viral hepatitis, including hepatitis A, B, C, E, Epstein-Barr virus (EBV), cytomegalovirus (CMV), human herpes virus (HHV) 6/7 and herpes simplex virus (HSV) were negative 113 114 (Supplementary Table 2). One case had weakly positive antinuclear antibodies (ANA; titre 115 1:80), but otherwise autoimmune markers, [immunoglobulins, antinuclear antibodies (ANA), anti-mitochondrial antibodies (AMA), anti-smooth muscle antibodies (ASMA), anti-liver-116 117 kidney microsomal (anti-LKM) antibody and tissue transglutaminase antibody (TTG)] were negative. Four of the children had liver biopsies, which all showed evidence of lobular hepatitis 118 119 with periportal and interface inflammation, bile duct proliferation and ballooning of 120 hepatocytes, but no evidence of confluent fibrosis (Figures 1e-j). Two cases required transfer 121 to a specialist liver unit due to significant synthetic liver dysfunction. Both improved with steroid therapy and neither required liver transplantation. There were no deaths and the median 122 123 duration of hospital stay was 10 days (range 5-32 days).

124

125 Genome sequencing

126 As the epidemiology was in keeping with the emergence of an infectious pathogen, we undertook metagenomic and target enrichment sequencing and real-time PCR on all available 127 clinical samples of cases, including plasma (n=9), liver biopsies (n=4), throat swabs (n=6), 128 129 faecal samples (n=7) and a rectal swab (n=1), obtained between 7 to 80 days from initial 130 symptom onset (Figures 2a-d, Supplementary Tables 3-5). Metagenomic sequencing was 131 carried out using protocols designed to identify both RNA and DNA viruses. Semi-agnostic 132 target enrichment sequencing was also performed using VirCapSeq-VERT Capture probes that 133 target the genomes of 207 viral taxa known to infect vertebrates (Supplementary 134 Information). The most frequently detected viral genomes in affected patient plasma were adeno-associated virus 2 (AAV2) in 9/9 patients (range 152-24.968 sequence reads per million) 135 136 and at a lower read count, HAdV-F41 or HAdV-C (types 1, 2, 5 and 6 could not be 137 distinguished reliably due to low read counts) in 6/9 patients (range 0-1.66 reads per million). HHV6B was detected at low level in the liver biopsy samples of 2/4 patients by PCR and 3/4 138 139 plasma samples by NGS but was not confirmed by PCR in plasma in 9/9 patients (Figures 2e, 140 **3a**).

141

AAV2 was detected in 9/9 serum samples and 4/4 liver biopsies, 1/7 faecal, 1/1 rectal and 1/6 142 143 throat swab samples. Near full genomes of AAV2 were detected in all 9 patients and contained two large open reading frames corresponding to rep and cap, flanked by ITR regions. Seven 144 145 distinct lineages of AAV2 were noted (Figure 4a) within a cluster containing 4 AAV2 genomes detected in France between 2004 and 2015. Two of three identical sequences were 146 known to have come from a single household and the third occurred around the same time but 147 148 was not known to be otherwise linked. Several mutations within the VP1-3 genes were noted to be over-represented in the sequences derived from patients with hepatitis when compared 149 with reference sequences (Figure 4c). Notably, 9 of the capsid gene mutations over-150

represented in these cases (V151A, R447K, T450A, Q457M, S492A, E499D, F533Y, R585S
and R588T) are associated with a sub-lineage of AAV2 (AAVv66) that has an altered
phenotype, including substantial evasion of neutralising antibodies directed against wild-type
AAV2, enhanced production yields, reduced heparin binding and increased virion stability.
Intrathecal injection of AAVv66 in mice resulted in widespread CNS transduction compared
with more localised spread in mice injected with wildtype AAV2.⁸

157

158 HAdV was detected in 3/9 plasma samples, 3/4 liver biopsies, 2/6 throat swabs, 4/7 faecal 159 samples and 1/1 rectal swab (Figure 2b; Supplementary Table 3). The lower detection of HAdV by PCR compared to enrichment sequencing likely reflects slightly lower sensitivity of 160 161 the PCR assay. However low numbers of positive samples using both assays may reflect the 162 fact that plasma is a suboptimal sample type for HAdV detection (whole blood samples were 163 unavailable). A full genome of HAdV-F41 was retrieved from a faecal sample (accession 164 number pending) and was found to be closest to two genomes reported from Germany in 2019 165 and 2022 (Figure 2b). As described above, HHV6B was detected at low read number (0.41-3.89 reads per million) in 3 out of 4 plasma samples (Figure 3a, Supplementary Table 4). 166 167 The remaining clinical samples were excluded from analysis for HHV by sequencing because 168 murine CMV had been added as an extraction control during routine clinical investigation. All 169 9 plasma samples tested negative by PCR for HHV6, HSV, CMV and EBV. Two liver biopsy 170 specimens tested positive for HHV6 (Ct 33 and 36). Contigs matching to other known human 171 pathogens, including human coronavirus NL63, rhinovirus C, enterovirus B, human 172 parainfluenza virus 2 and 3, norovirus, as well as other beta- and gammaherpesviruses were 173 also detected although not consistently across cases (Supplementary Table 2). These were detected by both sequencing and PCR. 174

176 To investigate the presence of AAV2 and the candidate helper viruses HAdV and HHV6B in case samples, we undertook a series of case-control studies using plasma by sequencing and 177 by real-time PCR (Figures 2b-e, 3a). Higher read counts of HAdV (p=0.0545), AAV2 178 179 (p<0.001) and HHV6B (p=0.0059) were found in cases versus healthy controls (Supplementary Figures 1a,1b). Metagenomic and target enrichment sequencing from the 13 180 age-matched healthy control samples (group 1) revealed no evidence of AAV2, HAdV or 181 HHV6B in plasma, although low read counts of EBV, CMV and HHV6A were detected 182 183 (Figure 3a, Supplementary Figure 1c-j)). 12 HAdV-infected controls (10 diagnosed by 184 nasopharyngeal aspirate, 1 by nose swab and 1 by stool) with normal liver function (group 2) were found to have no evidence of AAV2. HAdV reads were also detected in 6/12 185 plasma/serum samples, and 9/12 of this group had a herpesvirus detected, including 2/12 with 186 187 detectable numbers of HHV6B reads (1050-5062 reads per million), confirmed by PCR (Figure 2a; Supplementary Table 6; Supplementary Figure 1). In keeping with the 188 189 possibility of reactivation of HHV6B, 6/12 of this control group had been admitted to hospital 190 with a critical illness.

191

192 *Real-time PCR*

To quantify the level of AAV2 and to further investigate the presence of the helper viruses HAdV and HHV6B, we carried out real-time PCR in case plasma and control sera/plasma. We also included a third control group of patients with hepatitis of alternative aetiology, half of whom had been admitted to critical care (**Figures 2c-e**). Significance differences between groups for Ct values and viral loads/ml of plasma were calculated using the Mann-Whitney test. AAV2 PCR of plasma from 9/9 cases was positive with a median estimated copy number of 8,058,879 copies/ml (**Figure 2c; Supplementary Figure 2**). 2/9 case plasma were positive

200 for HAdV-F41 by PCR (Figure 2d), and all tested negative by PCR for HHV6 DNA (Figure
201 2e).

202

203 SARS-CoV-2 infection

204 Routine clinical investigation detected SARS-CoV-2 nucleic acid in nasopharyngeal samples 205 from 2/9 children, one of whom was also seropositive. The other developed infection after the 206 onset of hepatitis. SARS-CoV-2 was not detected by PCR and sequencing in any clinical 207 samples, including liver samples, in cases or controls. Nevertheless, to investigate the 208 possibility that unexplained hepatitis in children might relate to a preceding SARS-CoV-2 infection or other seasonal coronaviruses, we carried out serology. IgG antibody titres were 209 measured quantitatively against SARS-CoV-2 trimeric spike (S) protein, N-terminal domain 210 (NTD), receptor binding domain (RBD) and nucleocapsid (N), and the human seasonal 211 212 coronaviruses (HCoVs) 229E, OC43, NL63 and HKU1. Electrochemiluminescence assay 213 (MSD-ECL) for coronavirus-specific IgG revealed high levels of prior exposure to seasonal 214 coronaviruses; NL63 (9/9) and OC43 (7/9) (Supplementary Figure 3a). In comparison, 215 plasma from 5/9 children displayed reactivity with HKU1 and 3/9 with 229E. Plasma from three children reacted with SARS-CoV-2 N, a fourth was considered weak positive in 216 comparison with the reference range of known negative individuals (Supplementary Figure 217 **3b**). This child was one of 3/4 of the N-positive children displaying reactivity with S, NTD and 218 219 RBD, confirming likely SARS-CoV-2 exposure. Plasma from the fourth child reacted with N 220 only, while plasma from an additional two children reacted with S, NTD and RBD only (no N 221 reactivity) in keeping with exposure to natural infection in the absence of vaccination. In 222 summary, 6/9 (67%) of the children displayed evidence of prior exposure to SARS-CoV-2; this 223 level was comparable to SARS-CoV-2 seroprevalence in children aged 5-11 years in Scotland

between 14th March and 4th April 2022 (time period when clinical samples of cases were
obtained), reported as between 59% (95% CI 50.6-71.2) and 67% (56.2-77.6%).⁹

226

227 HLA typing

To investigate the possibility that some children might be more susceptible to non-A-E 228 hepatitis, cases and local controls (all of white ethnicity) were genotyped using high resolution 229 typing for all HLA loci (HLA-A, B, C, DRB1, DRB3/4/5, DQA1, DQB1, DPA1 and DPB1) 230 using the AllType[™] FASTplex[™] NGS Assay (One Lambda). We analysed HLA allele 231 232 positivity in the nine cases plus an additional 11 ISARIC CCP-UK study patients (n=20 in total) compared to 64 Scottish platelet apheresis donor controls. Associations were observed 233 234 for the following alleles; DRB1*04:01 (OR 11.8 (95% CI 4.43-32.13), $p = 1.19 \times 10^{-9}$), DQA1*03:03 (OR 10.64 (4.07-28.18), $p = 3.8 \times 10^{-9}$) and DQB1*03:01 (OR 6.16 (2.49-15.21), 235 $p = 3.75 \times 10^{-6}$). The strength of associations and the known linkage disequilibrium between 236 237 HLA-DRB1*04:01 and associated alleles at other HLA loci indicates that DRB1*04:01 is the primary HLA associated allele. In patients, the HLA-DRB1*04:01 allele frequency was 0.50 238 and in local controls was 0.078. As a further reference, in 599,410 British/Irish North-West 239 European (BINWE) individuals on the Anthony Nolan register, the frequency of DRB1*04:01 240 is 0.114.¹⁰ Of the nine patients in which metagenomic and target enrichment sequencing was 241 undertaken, 8/9 carried the HLA-DRB1*04:01 allele and one carried the HLA-DR4 allele, 242 243 DRB1*04:07.

244

245 Conclusions/final statements

AAV2 detected independently by sequencing and by real-time PCR was present at significantly
higher frequency in cases of paediatric non-A-E hepatitis than controls. That this occurs in the
context of an increased frequency of the DRB1*04:01 allele when compared to a local blood

249 donor control population requires further investigation, but points to a T helper cell-mediated
250 pathological response triggered by exposure to HAdV and/or AAV2 infection.

251

252 AAV2 is a small non-enveloped single-stranded DNA virus of 4,675 nucleotides belonging to the species adeno-associated dependoparvovirus A (genus Dependoparvovirus, family 253 254 Parvoviridae)¹¹, first described in 1965 and occurs in up to 80% of the adult population, seroconversion occurring in early childhood following respiratory infection¹². In one 255 prospective study in the USA, the earliest seroconversion to AAV2 infection occurred in a 9-256 257 month-old child and the seroprevalence increased from 24.2% to 38.7% in 3 and 5-year-old children, respectively¹³. This age range coincides with that of the cases in this study, raising 258 259 the possibility of illness relating to primary infection rather than reactivation. 260 Dependoparvoviruses rely on coinfection with a helper virus for replication, most commonly 261 HAdV or a herpesvirus. The majority of clinical samples taken at presentation with hepatitis 262 were obtained more than 20 days after initial symptom onset, which could explain the absence 263 of a helper virus in some samples, and low viral loads (high Ct value) in positive samples. We detected two candidate helper viruses at low level in the cases; HAdV and HHV6B in 6/9 and 264 265 3/9 cases respectively (HHV6 was detected only by NGS at very low read counts and was not 266 confirmed by PCR in any of the cases). HHV6B was also present in two control groups that included children with severe HAdV infection and children with hepatitis of alternative 267 268 aetiology. As HHV-6 can establish latency and can integrate its genome into the human 269 chromosome, it may reactivate following concomitant illness (or immunosuppression) and may 270 represent either an opportunistic bystander or a pathogen.

271

We hypothesise that AAV2 may be directly implicated in the pathology of non-A-E hepatitisin children, following transmission as a co-infection with HAdV (or HHV6, although this is

274 much less likely) or as a result of reactivation following HAdV or HHV6 infection. Class II 275 HLA type may contribute to disease susceptibility. In keeping with an immune-mediated aetiology directed against AAV2-infected hepatocytes, hepatitis associated with the emergence 276 277 of a CD8+ cell-mediated response directed against the AAV2 viral capsid (VP1) was reported in early trials of AAV2 when used as a vector for gene therapy.¹⁴⁻¹⁶ An alternative explanation 278 279 is that AAV2 may be a useful biomarker of infection with HAdV (that may be the primary pathogen) that persists for a shorter time than AAV2. Most of our cases developed 280 281 gastroenteritis symptoms (vomiting and diarrhoea) lasting several days, several weeks before 282 the onset of jaundice. The opportunity to detect virus by sequencing was therefore likely reduced, as these samples were collected at a later stage. Further, whole blood samples would 283 284 have been likely to increase the sensitivity of detection, but only plasma samples were 285 available. We consider this alternative hypothesis to be less likely because we did not detect 286 AAV2 in a control group of children with HAdV infection who had normal liver function.

287

HAdV41 is a common cause of diarrhoea in young children¹⁷ and adenovirus-associated hepatitis has been described, particularly among immunocompromised individuals.¹⁸ However, it has not previously been associated routinely with severe hepatitis. In the recent outbreaks of unexplained hepatitis in children, it has been inconsistently reported.^{4-6,19-21} HHV6B is a human herpesvirus that is associated with the childhood illness roseola infantum (sixth disease) and a self-limiting otherwise non-specific febrile illness.²² Seroconversion usually occurs by 2 years of age and hepatitis occasionally occurs in immunocompetent individuals.

295

We investigated the possibility that unexplained cases of hepatitis may be linked to prior COVID-19 infection. Direct SARS-CoV-2 liver injury seems unlikely, since few of our cases (2 of 9) were SARS-CoV-2 PCR-positive on admission, and we did not identify SARS-CoV-

2 by PCR or sequencing in any of the clinical samples from cases, including liver biopsies. 300 Further, the SARS-CoV-2 antibody positivity in hepatitis cases was within community 301 positivity rates at that time.³ This is in keeping with a case-control analysis by UKHSA 302 reporting no difference in SARS-CoV-2 PCR positivity between hepatitis cases and children 303 presenting to emergency departments between January and June 2022.³ Nevertheless, we 304 cannot fully exclude a post-COVID-19 immune-mediated phenomenon in susceptible children.

305

306 There are several limitations to this study. Firstly, the presence of AAV2 in cases but not 307 controls may have arisen due to seasonal variation in AAV2 transmission, as some controls were sampled earlier than cases. Secondly, the presence of AAV2 in cases is an association 308 309 and may not represent direct aetiology; rather the AAV2 may be a useful biomarker of recent 310 HAdV (or less likely HHV6B) infection. We do not consider it likely that AAV2 simply represents a marker of liver damage because it was not present in cases of severe hepatitis of 311 alternative aetiology. Thirdly, while the strong association of the HLA-DRB1*04:01 allele, 312 known to be associated with autoimmune hepatitis²³ and extra-articular manifestations of 313 rheumatoid arthritis,²⁴ may represent a disease susceptibility gene, local population structure 314 315 could result in an over-estimate of significance. Nonetheless it is plausible that an HAdV 316 infection, along with a coinfecting or reactivated AAV2 infection has resulted, for a proportion 317 of children who are more susceptible (due to the class II HLA allele HLA-DRB1*04:01), in a 318 more severe outcome than might normally be expected for these commonly circulating viruses. 319 The recent clustering of cases may have arisen in part because of changes in exposure pattern 320 to HAdV, AAV2 and HHV6B as a result of the COVID-19 pandemic. Faecal HAdV usually 321 follows seasonal trends with maximal rates of detection in younger age groups. However, the circulation of respiratory viruses was interrupted in 2020 by the implementation of non-322 323 pharmaceutical interventions, including physical distancing and travel restrictions, instituted

324	to mitigate SARS-CoV-2 transmission. These measures may have created a pool of susceptible
325	younger children, resulting in much higher rates of HAdV and potentially AAV2 circulation in
326	this population of naïve children when the COVID-19 restrictions were relaxed.
327	
328	Larger case-control studies are urgently needed to investigate the role of AAV2, HAdV,

329 HHV6B and HLA type in the aetiology of unexplained non-A-E paediatric hepatitis.

330 Retrospective testing of samples from cases of unexplained hepatitis in children is also

indicated. Ongoing work to measure IgM and IgG responses against AAV2, HAdV and

- HHV6B may help to delineate whether the AAV2 has been acquired as a primary co-infection
- 333 or reactivation.



337 Figure 1: Epidemiology and histology of liver biopsies in Scottish children with AAV2 338 and HAdV-associated hepatitis (a) Emergence of acute non-A to E hepatitis in children 339 Cases of non-A-E hepatitis in children 10 years and under in Scotland, 11 January to 20 June 2022 (pink).³ Cases of HAdV (children <5 years: red, children 5-10 years: purple) (b), SARS-340 CoV-2 (black) (c) and HHV6 (blue) (d) in children aged 10 years and under in Scotland January 341 342 2019 to June 2022. The histology of Case 3 (CVR3) is shown in panels (e-j). A low-power liver biopsy image (e) showing expansion of the portal tracts by inflammatory cells (1), 343 344 interface hepatitis (2), feathering (ballooning) change of hepatocytes (3) and apoptotic 345 hepatocytes (4). Mild steatosis is present in some zone 2 hepatocytes (5). A medium power view of the same biopsy (f) illustrates an affected portal tract showing a mixed infiltrate of 346 347 inflammatory cells (lymphocytes, plasma cells, eosinophils and neutrophils). Vessels and bile 348 ducts are preserved. A high-power picture (g) of the liver parenchyma showing feathering (ballooning) change in the hepatocytes (1), focal mild steatosis (2), focal bile canaliculi 349 350 plugging (3) and lipofuscin pigment (4). An apoptotic hepatocyte (**h**) is highlighted with an 351 asterisk *. A reticulin stain of the same biopsy (i) highlights an increased density of fibres in areas of inflammation and some change of the zone 2 parenchyma. A Masson trichrome stain 352 353 showing collagen in blue (i) within portal tracts and mild staining extending around some 354 hepatocytes.

355



359 Figure 2. (a) Heatmap of HAdV and AAV-2 reads detected in hepatitis cases by target

360 enrichment sequencing. Samples obtained for routine clinical investigation (plasma, liver,

- 361 faeces, rectal and throat swab) were retrospectively sequenced following DNA or RNA
- 362 extraction. AAV2 read counts are shown from 0->100 reads/million in green (upper row) and
- HAdV read counts are shown from 0->10 reads/million in red (lower row). (b) Heatmap of
- 364 viral reads from plasma in cases and plasma/sera from controls. Plasma samples from
- 365 cases, and plasma or sera samples from children with HAdV infection and age-matched
- 366 healthy controls were sequenced following DNA or RNA extraction. AAV2 read counts are
- shown from 0->100 reads/million in green and HAdV read counts are shown from 0->10
- 368 reads/million in red. The number of days between initial symptom onset and sample are
- 369 indicated. (c) AAV2 real-time PCR in cases versus controls. The estimated detection limit

of the assay (Ct=31.9) is shown (dotted line) Error bars represent median. Statistical analysis

- 371 was performed using Mann-Whitney test. (d) HAdV41 real-time PCR in cases versus
- 372 controls. (e) HHV6 real-time PCR in cases versus controls.
- 373
- 374
- 375
- 376
- 377
- 378
- 379
- 380







388

Figure 4 (a) Phylogeny of AAV2 genomes from cases 1-9. The nine AAV2 genome

sequences generated from the plasma samples via target enrichment (highlighted in red) were

- aligned with a range of the closest AAV sequences from La Bella *et al.*²⁵ and Cordey *et al.*²⁶ and Cordey *et al.*²⁶
- 392 IQ-TREE 2 was used to find the optimal model (TIM+F+R3) and create a maximum

393	likelihood (ML) phylogenetic tree with 1000 bootstrap replicates (displayed on the branches).
394	The tree is midpoint rooted. AAV2 reference sequences are denoted by accession number,
395	country and year of sampling (b) Phylogeny of HAdV41 genome from case 5 A near-full
396	HAdV41 genome sequence from the faecal sample of patient 5 (highlighted in red) was
397	combined with complete genomes of HAdV41 from GenBank. After alignment with
398	MAFFT, IQ-TREE 2 was used to determine the optimal evolutionary model (K2P+R2) and
399	to construct a ML phylogenetic tree with 1000 bootstrap replicates. The tree is midpoint
400	rooted. HAdV41 reference sequences are denoted by accession number, country and year of
401	sampling. (c) Key mutations and hierarchical clustering of AAV2 genomes Mutations in
402	published AAV2 sequences are highlighted in (blue) and case sequences (green) (d)
403	Mutations over-represented in cases versus controls Mutations in VP1-3, Rep78 and 52
404	and AAP are highlighted by % representation in case sequences (green) and published
405	sequences (blue)

406

408 Methods

409 ISARIC CCP-UK recruitment & DIAMONDS/ study

Ethical approval for the ISARIC CCP-UK study was given by the South Central-Oxford C 410 411 Research Ethics Committee in England (13/SC/0149), the Scotland A Research Ethics Committee (20/SS/0028), and the WHO Ethics Review Committee (RPC571 and RPC572). 412 413 Children aged <16 years were recruited by written informed consent (parent or guardian) from 414 the ISARIC WHO CCP-UK cohort admitted to hospital with elevated transaminases (defined as ALT >400 iU/L and/or AST >400 iU/L) that was not due to viral hepatitis A-E, autoimmune 415 416 hepatitis or poisoning. Control samples were obtained from children (aged <16 years) recruited 417 to the Diagnosis and Management of Febrile Illness using RNA Personalised Molecular Signature Diagnosis (DIAMONDS), an ongoing multi-country study that aims to develop a 418 molecular diagnostic test for the rapid diagnosis of severe infection and inflammatory diseases 419 420 using personalised gene signatures (ISRCTN12394803). Ethical approval was given by London-Dulwich Research Ethics Committee (20/HRA/1714). Controls included healthy 421 controls (n=13), children with PCR-confirmed adenoviral infection with normal transaminases 422 423 (n=12), and children with raised transaminases without adenoviral infection (n=33), recruited between 19 May 2020 to 8 January 2022. 424

425

426 Viral PCR

427 RNA extraction was carried out using the Biomerieux Easymag generic protocol. 300ul of
428 plasma or sera was extracted and eluted into 80 ul of water.

429 AAV2 quantitative PCR was performed to detect a 62bp amplicon of the AAV2 inverted
430 terminal repeat region (ITR) as previously described²⁷ using the forward ITR primer 5'-

431 GGAACCCCTAGTGATGGAGTT-3') the ITR primer 5'and reverse CGGCCTCAGTGAGCGA-3'). The AAV2 ITR hydrolysis probe was labelled with fluorescein 432 with Hole 433 (6FAM) and quenched Black quencher (BHQ) 5'-[6FAM]-434 CACTCCCTCTCTGCGCGCTCG-[BHQ1]3'). AAV2 primers and probe were synthesised by Merck Life Sciences UK Limited, United Kingdom. Quantitative PCR analysis was performed 435 using the ABI7500 Fast Real-Time PCR system (Applied Biosystems). LUNA Universal One-436 Step RT PCR kit (New England Biolabs) was used for the amplification and detection of the 437 AAV2 ITR target. qPCR reactions were performed in a 20µl volume reaction (Luna Universal 438 439 One-Step reaction mix, Luna WarmStart RT enzyme mix, 400nM forward and reverse primers, 200nM AAV2 ITR probe and 1-2.5µl of template DNA) as per manufacturer's instructions. To 440 441 quantify the number of copies, serial dilutions of plasmid containing the 62bp ITR product 442 were used to generate a standard curve which was then used to interpolate the copy number of 443 AAV2 copies in the samples. Wells with no template were used as negative controls. qPCR 444 reactions were performed in triplicate. The qPCR program consisted of an initial reverse 445 transcription step at 55 C for 10 minutes, an initial denaturation at 95 C for 1 minute followed by 45 cycles 95 C denaturation for 10 seconds and extension at 58 C for 1 minute. A qPCR 446 447 detection limit of 31.9 was calculated as the threshold Ct value at the last dilution of DNA 448 standards that were within the linear range.

449

The West of Scotland Specialist Virology Centre, NHS Greater Glasgow and Clyde conducted diagnostic real-time PCR with reverse transcription to detect HAdV, SARS-CoV-2-positive samples and other viral pathogens associated with hepatitis (e.g. Hepatitis A-E), following nucleic acid extraction utilizing the NucliSENS easyMAG and Roche MG96 platforms. HHV6²⁸ and HAdV41²⁹ were tested by qPCR as previously described using Invitrogen platinum qPCR mix (Cat no 11730-025) and Quanta Biosciences qPCR mix Mastermix

456 (Cat.No. 733-1273) respectively on an ABI7500 and amplified for 40 cycles. A 6ul extract was
457 amplified in a total reaction volume of 15ul.

458 *Measurement of antibody response to coronaviruses by electrochemiluminescence*

459 IgG antibody titres were measured quantitatively against SARS-CoV-2 trimeric spike (S) protein, N-terminal domain (NTD), receptor binding domain (RBD) or nucleocapsid (N), and 460 461 the human seasonal coronaviruses (HCoVs) 229E, OC43, NL63 and HKU1 using MSD V-462 PLEX COVID-19 Coronavirus Panel 2 (K15369) and Respiratory Panel 1 (K15365) kits. 463 Multiplex Meso Scale Discovery electrochemiluminescence (MSD-ECL) assays were performed according to manufacturer instructions. Samples were diluted 1:5000 in diluent and 464 465 added to the plates along with serially diluted reference standard (calibrator) and serology 466 controls 1.1, 1.2 and 1.3. Plates were read using a MESO Sector S 600 plate reader. Data were 467 generated by Methodological Mind software and analysed using MSD Discovery Workbench 468 (v4.0). Results are expressed as MSD arbitrary units per ml (AU/ml).

469

470 Metagenomic sequencing

471 Residual nucleic acid from 27 samples (9 patients with a combination of plasma, liver, faeces, 472 rectal and throat/nose samples), 12 HAdV-positive and 13 healthy controls (control samples were either plasma or sera) underwent metagenomic next-generation sequencing at the CVR. 473 474 Briefly, each nucleic acid sample was split in two library preparations, to improve the chances 475 of detecting RNA and DNA viruses. The protocol applied for improved detection of RNA 476 viruses included treatment with DNaseI (Ambion DNase I, ThermoFisher), ribosomal 477 depletion (Ribo-Zero Plus rRNA Depletion Kit, Illumina), except for plasma samples, reverse 478 transcription (SuperScript III, Invitrogen) and double-strand DNA synthesis (NEBNext® UltraTM II Non-Directional RNA Second Strand Synthesis Module, NEB). The protocol 479

480	applied to detect DNA viruses included partial removal of host DNA (NEBNext® Microbiome
481	DNA Enrichment Kit, NEB). Following this, both sets of samples were used to prepare libraries
482	using the KAPA LTP kit (Roche) with unique dual indices (NEBNext® Multiplex oligos for
483	Illumina, NEB). The resulting libraries were pooled in equimolar amounts and sequenced using
484	a NextSeq500 (Illumina) to obtain paired end reads using 150X150 cycles.
485	
486	Target enrichment sequencing
487	Following on the library preparation step described above, DNA and RNA derived libraries
487 488	Following on the library preparation step described above, DNA and RNA derived libraries were pooled separately and were incubated with the VirCapSeq-VERT Capture Panel probes
487 488 489	Following on the library preparation step described above, DNA and RNA derived libraries were pooled separately and were incubated with the VirCapSeq-VERT Capture Panel probes (Roche) following the manufacturer's guidelines. The Roche VirCapSeq-VERT Capture Panel
487 488 489 490	Following on the library preparation step described above, DNA and RNA derived libraries were pooled separately and were incubated with the VirCapSeq-VERT Capture Panel probes (Roche) following the manufacturer's guidelines. The Roche VirCapSeq-VERT Capture Panel covers the genomes of 207 viral taxa known to infect vertebrates (including humans). Enriched
487 488 489 490 491	Following on the library preparation step described above, DNA and RNA derived libraries were pooled separately and were incubated with the VirCapSeq-VERT Capture Panel probes (Roche) following the manufacturer's guidelines. The Roche VirCapSeq-VERT Capture Panel covers the genomes of 207 viral taxa known to infect vertebrates (including humans). Enriched DNA and RNA- derived libraries were further amplified using 14 PCR cycles, pooled and

492 sequenced using a NextSeq500 (Illumina) to obtain paired end reads using 150X150 cycles.

493

494 Bioinformatics analysis

Reads for each sample were first quality checked, Illumina adapters were trimmed using Trim 495 496 Galore (https://github.com/FelixKrueger/TrimGalore), and reads were then mapped to the human genome using BWA-MEM (https://github.com/lh3/bwa). Only reads that did not map 497 498 to the human genome were used for metagenomic analyses. Non-human reads were then de 499 novo assembled using MetaSPAdes (https://github.com/ablab/spades) to generate contigs for 500 each sample. Contigs were then compared against a protein database of all NCBI RefSeq 501 organisms (including virus, bacteria, eukaryotes) with BLASTX using DIAMOND (https://github.com/bbuchfink/diamond). In addition, non-human reads for each sample were 502

aligned to a small panel of HAdV NCBI RefSeq genomes (HAdV-A, B1, B2, C, D, E, F, 1, 2,
5, 7, 35, 54 as well as HAdV-F41).

505

506 The nine AAV2 near-complete genome contigs from the plasma samples were assembled and 507 were compared with sequences in GenBank using BLASTN (nt database); each AAV2 had 508 numerous close hits (exhibiting >95% similarity across 95% of the genome) with various existing AAV2 sequences, those most closely related were reported in a recent publication²⁵ A 509 510 representative range of AAV2 sequences were selected and combined with the AAV sequences 511 de novo assembled here, aligned with MAFFT, the terminal ends of the alignment were 512 trimmed off, and IQ-TREE 2 was used (TIM+F+R3 model) to infer a phylogenetic tree. For 513 the single HAdV41 genome de novo assembled, all available HAdV41 complete genomes were 514 downloaded from GenBank aligned with MAFFT, and IQ-TREE2 was used (K2P+R2 model) to 515 infer a phylogenetic tree.

516

517 HLA typing

High resolution typing for all HLA loci (HLA-A, B, C, DRB1, DRB3/4/5, DQA1, DQB1,
DPA1 and DPB1) was performed using AllTypeTM FASTplexTM NGS Assay (One Lambda)
run on an Illumina Mi-Seq platform. HLA typing was undertaken on 20 ISARIC consented
patients. One patient was omitted from analysis as they were a sibling of another case. HLA
types from 64 Scottish National Blood Transfusion Service apheresis platelet donors, selfidentified as White British (n=15) or White Scottish (n=49) were used as control samples for
comparison with patient HLA phenotype frequencies.

525

526 Statistics

527	Differences between cases and control groups were calculated using Fisher's Exact Test for
528	categorical variables and Mann-Whitney test for continuous variables.
529	
530	HLA analysis used the Bridging ImmunoGenomic Data-Analysis Workflow Gaps
531	(BIGDAWG) R package to derive OR and corrected p values for individual HLA alleles. ³⁰
532	Bonferroni corrected p value significance threshold, adjusted for multiple comparisons (168
533	HLA alleles), was $p < 3.0 \times 10^{-4}$. Significance differences between groups for other
534	comparisons were calculated using Mann-Whitney test or t-test as appropriate.
535	
536	Data and code availability: available on request
537	
538	Funding
539	The work was funded by Public Health Scotland, the National Institute for Health Research
540	(NIHR; award CO-CIN-01) and the Medical Research Council (MRC; grants MC UU
541	1201412, MC_PC_19059 & MC_PC_22004). DIAMONDS is funded by the European Union
542	Horizon 2020 programme; grant 848196).
543	
544	
545	
546	

547 Acknowledgements

548	We wish to acknowledge the contribution of the participating children and their parents who
549	agreed to participate in the ISARIC CCP-UK and DIAMONDS studies, and the research teams
550	who recruited the patients. We also acknowledge the invaluable input of Eric J. Kremer from
551	the Institut de Génétique Moléculaire de Montpellier, Université de Montpellier.
552	
553	Competing interest declaration
554	The authors have no competing interests
555	
556	Supplementary Information is available for this paper.
557	
558	Correspondence and requests for materials should be addressed to Professor Emma C
559	Thomson.
560	
561 562	Reprints and permissions information is available at <u>www.nature.com/reprints</u> .
563	

564 Supplementary information

	Cases		Controls									
	(n=9)	Healthy	Р	HAdV	Р	Elevated	Р					
		(n=13)	value*	infection with	value*	transaminases	value*					
				normal		with no						
				transaminases		HAdV						
				(N=12)		infection						
						(n=33)						
Sex - male	4	10 (76.9)	0.187	7 (58.3)	0.67	18 (52.9)	0.71					
	(44.4)											
Age (years)	3.9	4.1 (3.6-4.9)	0.89	1.6 (1.1-3.3)	< 0.001	9.2 (6.7-13.6)	0.001					
	(3.4-											
	5.1)											
Recruitment	14	6 Nov 2020 -	-	22 May 2020	-	9 Sep 2020 - 8	-					
period	March	6 Jul 2021		- 22 Dec 2021		Jan 2022						
	2 - 4											
	April											
	2022											

565 Supplementary Table 1. Characteristics of cases and controls

566 *Fisher's exact or Mann-Whitney test

0.0

577 Supplementary Table 2. Clinical laboratory results of the nine non-A-E hepatitis cases in

578 Scottish children

Pa	tient	1	2	3	4	5	6	7	8	9
	Blood	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative
	Throat/nose	NT	Negative	Positive	Negative	Negative	Negative	Negative	Positive	NT
HAdV				(Ct 38)					(Ct 30)	
PCR	Stool	Negative	Negative	Negative	Negative	Positive	Positive	Negative	Positive	NT
						(Ct 31)	(Ct 34)		(Ct 31)	
HAdV 41	Blood	Negative	Negative	Positive	Negative	Negative	Negative	Negative	Negative	Positive (Ct
PCR				(Ct 36)						37)
	IgM	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative
Hepatitis A	PCR	Negative	Negative	Negative	Negative	Negative	NT	NT	NT	NT
Hepatitis B	sAg	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative
		Negative	NT (IgG	Negative	Negative	Negative	Negative	NT	NT	Negative
Hepatitis C	PCR		negative)							
Hepatitis E	IgM	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative
	PCR	Negative	Negative	Negative	Negative	Negative	NT	NT	NT	NT
Parvovirus	IgM	Negative	NT	Negative	Negative	Negative	Negative	Negative	Negative	NT
B19		NT	Negative	NT	NT	NT	NT	NT	NT	NT
	PCR									
CMV	IgM	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative
EBV	IgM	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative
Enterovirus	Blood	Negative	Negative	Negative	Negative	Negative	NT	NT	Negative	NT
PCR										
HSV PCR	Blood	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative
HIV Ag/Ab	Blood	Negative	Negative	NT	Negative	Negative	Negative	Negative	Negative	NT
	Blood	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative
HHV6/7	PCR									
Respiratory	Throat/ nose	NT	Negative	hCoV-	Negative	Paraflu	Paraflu 2	Negative	Rhino/EV	NT
viral PCR*				NL63		3	Rhino/EV		(Ct 36)	
SARS-		Negative	Negative	Negative	Negative	Positive	Positive	Negative	Negative	Negative
CoV-2 PCR	Throat/ nose									
Liver		Positive		Negative	Positive					
	CMV, EBV,	HHV6			HHV6					Negative
	HSV,HHV6/7	PCR+			PCR (Ct					
	PCR	(Ct 33)			36)					
Other								Stool		
sample								Norovirus		
								PCR		
								Positive		

579

580 Abbreviations – PCR, polymerase chain reaction; CMV, cytomegalovirus; EBV, Epstein-Barr Virus;

581 HSV, Herpes Simplex virus, HIV, Human Immunodeficiency Virus; HHV, Human herpesvirus; PCR,

582 polymerase chain reaction; NT, not tested

583 Supplementary Table 3 Read counts per million of AAV2 and HAdV in cases following



584 target enrichment sequencing

586 Supplementary Table 4 Read counts per million of human herpesviruses in cases

587 following target enrichment sequencing

Patient ID		1	1	2	3	4	5	6	7	8	9	10	11	12	13
		ONA					-	0.00	0.00	0.00	0.00				
	HSV1 F	RNA					E F	0.00	0.00	0.00	0.00				
	0	ONA						0.00	0.00	0.00	0.00		F	leads pe	er million
	HSV2 F	RNA						0.00	0.00	0.00	0.00		C	1	>10
	C	ONA						0.00	2.14	0.00	0.00				
	VZV F	RNA						0.00	0.00	0.00	0.00				
		DNA						0.53	0.00	0.00	0.00				
	EBV F	RNA						0.00	0.00	0.00	0.00				
Casas	L	DNA						0.00	0.00	9.85	0.00				
Cases							H	0.00	0.00	0.00	0.21				
							- F	0.00	0.00	0.00	0.00				
							-	2 20	2 90	0.00	0.00				
	HHV6B F	RNA					_	0.00	0.00	0.00	0.00				
	C	ONA						0.00	0.00	0.00	0.00				
	HHV7 F	RNA					-	0.00	0.00	0.31	0.00				
	0	ONA						0.00	0.00	0.00	0.00				
	HHV8 F	RNA						0.00	0.00	0.00	0.00				

589

590 Supplementary Table 5 Read counts per million of AAV2 and HAdV in case and

Patient ID 1 2 3 4 5 6 7 8 9 10 11 12 13 51 54 15 Day of infection 33 21 26 9 80 15 Adeno-associated virus 2 DNA 10327.10 774.15 10498.28 24967.81 401.41 Case 152.06 4477.52 1047.57 23572.34 RNA 133.25 0.00 12119.78 1016.67 0.00 380.98 35.21 805.89 3717.11 Adenovirus positive control 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 DNA RN/ 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Healthy control DN/ 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 RN/ 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Adenovirus C or F 0.00 0.60 0.00 0.00 1.45 677.57 0.00 0.00 0.00 Case DNA 1.66 RNA 0.00 0.00 0.00 0.00 0.00 0.00 Adenovirus positive control DNA 0.00 1.63 0.00 29950.78 0.00 16362.76 2860.62 0.00 347.34 450.33 0.00 0.00 0.00 0.00 0.00 13.74 0.00 0.00 0.00 0.00 0.00 2.36 0.00 0.00 Healthy control DN/ 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 RN/ 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

591 control sera following target enrichment sequencing

592

594 Supplementary Table 6 Read counts per million of HHV in case and control sera

595 following target enrichment sequencing

596

Patient ID	· ·		1	2	3	4	5	6	7	8	9	10	11	12	13
		DNA					1	0.00	0.00	0.00	0.00				
	HSV1	RNA						0.00	0.00	0.00	0.00				
		DNA						0.00	0.00	0.00	0.00			Reads p	er million
	HSVZ	RNA						0.00	0.00	0.00	0.00			0	>10
	1/7/	DNA						0.00	2.14	0.00	0.00				
	VZV							0.00	0.00	0.00	0.00				
	FBV	RNA						0.33	0.00	0.00	0.00				
	200	DNA						0.00	0.00	9.85	0.00				
Cases	CMV	RNA						0.00	0.00	0.00	0.21				
		DNA						0.00	0.00	0.00	0.00				
	HHV6A	RNA						0.00	0.00	0.00	0.00				
		DNA						3.39	3.89	0.00	0.41				
	HHV6B	RNA						0.00	0.00	0.00	0.00				
		DNA						0.00	0.00	0.00	0.00				
	HHV7	RNA						0.00	0.00	0.31	0.00				
		DNA						0.00	0.00	0.00	0.00				
	HHV8	KNA						0.00	0.00	0.00	0.00				
		DNA	0.00	3 35	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	n in the second s
	HSV1	RNA	0.00	11.38	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
		DNA	0.00	10.37	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
	HSV2	RNA	1.00	22.92	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
		DNA	0.00	2.68	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
	VZV	RNA	0.00	4.02	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
		DNA	0.00	167.63	0.00	0.00	0.00	0.00	0.00	0.00	1.64	0.00	272.40	0.00	
	EBV	RNA	0.00	9.03	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.38	17.58	
A		DNA	0.00	3634.02	56.82	123.87	0.00	8.26	0.00	0.00	25.24	0.00	0.00	0.00	
Adenovirus positive controis	CIVIV	RNA	0.00	3185.33	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
		DNA	0.00	1.67	0.44	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
	ппура		0.00	12.30	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1050.10	0.00	0.00	
	HHV6B	RNA	0.00	819 09	0.00	0.00	0.00	0.00	0.00	0.00	0.00	206.17	0.00	0.10	
	mittob	DNA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
	HHV7	RNA	2.00	10.54	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
		DNA	0.00	2.01	/5.91	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
	HHV8	RNA	0.00	1.34	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
		DNA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	HSV1	RNA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
		DNA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	HSV2	RNA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
		DNA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	VZV	RNA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
		DNA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.23	13.01	114.38	0.00	0.00
	EBV	RNA	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.10	0.00	0.00	0.00	0.18	0.00
Licolthy controls	~~~	DNA	0.00	17.06	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Healthy controls	CMV	RNA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
		DNA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	HINOA	DNA	0.00	0.00	0.00	0.08	0.00	0.00	0.10	0.00	0.00	0.00	0.00	5.10	0.00
	HHV6B	RNA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
		DNA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	HHV7	RNA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.10	0.00	0.00	0.00	0.00	0.00
		DNA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	HHV8	RNA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
			-												

597

599 Supplementary Figures



- 601 Supplementary Figure 1: AAV2, HAdV and human herpesvirus detection by target
- 602 enrichment sequencing in cases and controls. Read counts per million are plotted for
- 603 HAdV (a), AAV2 (b), HHV6B (c), HSV1 (d), HSV2 (e), VZV (f), HHV6A (g), HHV7 (h),
- 604 HHV8 (i) and CMV (j) in cases, healthy controls and HAdV positive children with normal =



605



607 PCR. Estimated copy numbers are shown, calculated using serial dilutions of a plasmid

608 containing the 62bp ITR product to generate a standard curve which was then used to

609 calculate the copy number of AAV2 in samples



612



614 OC43, NL63, HKU1 and b) SARS-CoV-2 in sera from paediatric hepatitis cases. Sera

from the paediatric hepatitis cases were screened for reactivity against SARS-CoV-2

616 nucleocapsid (N), spike (S), N-terminal domain of S (NTD) and receptor binding domain of

- 617 S (RBD) by electrochemiluminescence (MSD-ECL). Reactivity of the nine samples were
- 618 compared with three groups of sera from adults of known SARS-CoV-2 status; negatives
- 619 (n=30), vaccinated two doses (n=28) and infected (n=39).

620 **References**

622	1	Marsh, K. et al. Investigation into cases of hepatitis of unknown aetiology among
623		young children, Scotland, 1 January 2022 to 12 April 2022. Euro Surveill 27 ,
624		doi:10.2807/1560-7917.ES.2022.27.15.2200318 (2022).
625	2	World Health Organization. Severe acute hepatitis of unknown aetiology in children -
626		Multi-country, < <u>https://www.who.int/emergencies/disease-outbreak-</u>
627		<u>news/item/2022-DON400</u> > (2022).
628	3	UK Health Security Agency. Investigation into acute hepatitis of unknown aetiology
629		in children in England - Technical Briefing 4. (UKHSA, 2022).
630	4	Gutierrez Sanchez, L. H. et al. A Case Series of Children with Acute Hepatitis and
631		Human Adenovirus Infection. N Engl J Med, doi:10.1056/NEJMoa2206294 (2022).
632	5	Karpen, S. J. Acute Hepatitis in Children in 2022 - Human Adenovirus 41? N Engl J
633		<i>Med,</i> doi:10.1056/NEJMe2208409 (2022).
634	6	Kelgeri, C. et al. Clinical Spectrum of Children with Acute Hepatitis of Unknown
635		Cause. N Engl J Med, doi:10.1056/NEJMoa2206704 (2022).
636	7	Dunning, J. W. et al. Open source clinical science for emerging infections. Lancet
637		Infect Dis 14, 8-9, doi:10.1016/S1473-3099(13)70327-X (2014).
638	8	Hsu, H. L. et al. Structural characterization of a novel human adeno-associated virus
639		capsid with neurotropic properties. <i>Nat Commun</i> 11 , 3279, doi:10.1038/s41467-020-
640		17047-1 (2020).
641	9	Public Health Scotland. Enhanced Surveillance of Covid-19 in Scotland (Population-
642		based seroprevalence) - 5 week rolling estimate.,
643		https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-
644		in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-
645		seroprevalence-surveillance-1-june-2022/dashboard/> (2022).
646	10	Leen, G., Stein, J. E., Robinson, J., Maldonado Torres, H. & Marsh, S. G. E. The HLA
647		diversity of the Anthony Nolan register. <i>HLA</i> 97 , 15-29, doi:10.1111/tan.14127
648		(2021).
649	11	Srivastava, A., Lusby, E. W. & Berns, K. I. Nucleotide sequence and organization of
650		the adeno-associated virus 2 genome. J Virol 45, 555-564, doi:10.1128/JVI.45.2.555-
651		564.1983 (1983).
652	12	Atchison, R. W., Casto, B. C. & Hammon, W. M. Adenovirus-Associated Defective
653		Virus Particles. <i>Science</i> 149 , 754-756, doi:10.1126/science.149.3685.754 (1965).
654	13	Li, C. et al. Neutralizing antibodies against adeno-associated virus examined
655		prospectively in pediatric patients with hemophilia. Gene Ther 19 , 288-294,
656		doi:10.1038/gt.2011.90 (2012).
657	14	Martino, A. T. <i>et al.</i> Engineered AAV vector minimizes in vivo targeting of transduced
658		hepatocytes by capsid-specific CD8+ T cells. <i>Blood</i> 121 , 2224-2233,
659		doi:10.1182/blood-2012-10-460733 (2013).
660	15	Manno, C. S. <i>et al.</i> Successful transduction of liver in hemophilia by AAV-Factor IX
661		and limitations imposed by the host immune response. Nat Med 12 , 342-347,
662		doi:10.1038/nm1358 (2006).
663	16	Mingozzi, F. et al. CD8(+) T-cell responses to adeno-associated virus capsid in
664		humans. <i>Nat Med</i> 13 , 419-422, doi:10.1038/nm1549 (2007).

665	17	Rafie, K. et al. The structure of enteric human adenovirus 41-A leading cause of
666		diarrhea in children. <i>Sci Adv</i> 7, doi:10.1126/sciadv.abe0974 (2021).
667	18	Echavarria, M. Adenoviruses in immunocompromised hosts. Clin Microbiol Rev 21,
668		704-715, doi:10.1128/CMR.00052-07 (2008).
669	19	Baker, J. M. et al. Acute Hepatitis and Adenovirus Infection Among Children -
670		Alabama, October 2021-February 2022. MMWR Morb Mortal Wkly Rep 71, 638-640,
671		doi:10.15585/mmwr.mm7118e1 (2022).
672	20	Cooper, S. et al. Long COVID-19 Liver Manifestation in Children. J Pediatr
673		Gastroenterol Nutr, doi:10.1097/MPG.0000000000003521 (2022).
674	21	Deep, A., Grammatikopoulos, T., Heaton, N., Verma, A. & Dhawan, A. Outbreak of
675		hepatitis in children: clinical course of children with acute liver failure admitted to
676		the intensive care unit. Intensive Care Med, doi:10.1007/s00134-022-06765-3 (2022).
677	22	Zerr, D. M. et al. A population-based study of primary human herpesvirus 6 infection.
678		N Engl J Med 352 , 768-776, doi:10.1056/NEJMoa042207 (2005).
679	23	van Gerven, N. M. <i>et al.</i> HLA-DRB1*03:01 and HLA-DRB1*04:01 modify the
680		presentation and outcome in autoimmune hepatitis type-1. Genes Immun 16, 247-
681		252, doi:10.1038/gene.2014.82 (2015).
682	24	Lanchbury, J. S. et al. Strong primary selection for the Dw4 subtype of DR4 accounts
683		for the HLA-DQw7 association with Felty's syndrome. Hum Immunol 32 , 56-64,
684		doi:10.1016/0198-8859(91)90117-r (1991).
685	25	La Bella, T. et al. Adeno-associated virus in the liver: natural history and
686		consequences in tumour development. Gut 69, 737-747, doi:10.1136/gutjnl-2019-
687		318281 (2020).
688	26	Cordey, S. et al. Blood virosphere in febrile Tanzanian children. Emerg Microbes
689		Infect 10 , 982-993, doi:10.1080/22221751.2021.1925161 (2021).
690	27	Aurnhammer, C. et al. Universal real-time PCR for the detection and quantification of
691		adeno-associated virus serotype 2-derived inverted terminal repeat sequences. Hum
692		Gene Ther Methods 23, 18-28, doi:10.1089/hgtb.2011.034 (2012).
693	28	Gautheret-Dejean, A. et al. Development of a real-time polymerase chain reaction
694		assay for the diagnosis of human herpesvirus-6 infection and application to bone
695		marrow transplant patients. J Virol Methods 100, 27-35, doi:10.1016/s0166-
696		0934(01)00390-1 (2002).
697	29	van Maarseveen, N. M., Wessels, E., de Brouwer, C. S., Vossen, A. C. & Claas, E. C.
698		Diagnosis of viral gastroenteritis by simultaneous detection of Adenovirus group F,
699		Astrovirus, Rotavirus group A, Norovirus genogroups I and II, and Sapovirus in two
700		internally controlled multiplex real-time PCR assays. J Clin Virol 49, 205-210,
701		doi:10.1016/j.jcv.2010.07.019 (2010).
702	30	Pappas, D. J., Marin, W., Hollenbach, J. A. & Mack, S. J. Bridging ImmunoGenomic
703		Data Analysis Workflow Gaps (BIGDAWG): An integrated case-control analysis
704		pipeline. <i>Hum Immunol</i> 77 , 283-287, doi:10.1016/j.humimm.2015.12.006 (2016).
705		

CONSORTIA

ISARIC Comprehensive Clinical Characterisation Collaboration (ISARIC4C)

J Kenneth Baillie, Malcolm G Semple, Gail Carson, Peter JM Openshaw, Jake Dunning, Laura Merson, Clark D Russell, Maria Zambon, Meera Chand, Richard S Tedder, Saye Khoo, Lance CW Turtle, Tom Solomon, Samreen Ijaz, Tom Fletcher, Massimo Palmarini, Antonia Ho, Emma C Thomson, Nicholas Price, Thushan de Silva, Chloe Donohue, Hayley Hardwick, Wilna Oosthuyzen, Miranda Odam, Primrose Chikowore, Sara Clohisey, Andrew Law, Lucy Norris, Sarah Tait, Murray Wham, Richard Clark, Audrey Coutts, Lorna Donnelly, Angie Fawkes, Tammy Gilchrist, Katarzyna Hafezi, Louise MacGillivray, Alan Maclean, Sarah McCafferty, Kirstie Morrice, Lee Murphy, Nicola Wrobel, Sarah E McDonald, Victoria Shaw, Katie A. Ahmed, Jane A Armstrong, Lauren Lett, Paul Henderson, Louisa Pollock, Shyla Kishore, Helen Brotherton, Lawrence Armstrong, Andrew Mitra, Anna Dall, Kristyna Bohmova, Sheena Logan, Louise Gannon, Ken Agwuh, Srikanth Chukkambotla, Ingrid DuRand, Duncan Fullerton, Sanjeev Garg, Clive Graham, Tassos Grammatikopoulos, Stuart Hartshorn, Luke Hodgson, Paul Jennings, George Koshy, Tamas Leiner, James Limb, Jeff Little, Sheena Logan, Elijah Matovu, Fiona McGill, Craig Morris, John Morrice, David Price, Henrik Reschreiter, Tim Reynolds, Paul Whittaker, Thomas Jordan, Rachel Tayler, Clare Irving, Katherine Jack, Maxine Ramsay, Margaret Millar, Barry Milligan, Naomi Hickey, Maggie Connon, Catriona Ward, Laura Beveridge, Susan MacFarlane, Karen Leitch, Claire Bell, Lauren Finlayson, Joy Dawson, Janie Candlish, Laura McGenily, Tara Roome, Cynthia Diaba, Jasmine Player, Natassia Powell, Ruth Howman, Sara Burling, Sharon Floyd, Sarah Farmer, Susie Ferguson, Susan Hope, Lucy Rubick, Rachel Swingler, Emma Collins, Collette Spencer, Amaryl Jones, Barbara Wilson, Diane Armstrong, Mark Birt, Holly Dickinson, Rosemary Harper, Darran Martin, Amy Roff, Sarah Mills.

DIAMONDS Consortium

PARTNER: Imperial College (Coordinating Centre) (UK) Chief investigator/DIAMONDS coordinator: Michael Levin1 Principal and co-investigators (alphabetical order)1 Aubrey Cunnington; Jethro Herberg; Myrsini Kaforou; Victoria Wright Section of Paediatric Infectious Diseases Research Group (alphabetical order)1

Evangelos Bellos; Claire Broderick; Samuel Channon-Wells; Samantha Cooray; Tisham De (database work package lead); Giselle D'Souza; Leire Estramiana Elorrieta; Diego Estrada-Rivadeneyra; Rachel Galassini (Clinical Trial Manager); Dominic Habgood-Coote; Shea Hamilton (Proteomics); Heather Jackson; James Kavanagh; Mahdi Moradi Marjaneh; Stephanie Menikou; Samuel Nichols; Ruud Nijman; Harsita Patel; Ivana Pennisi; Oliver Powell; Ruth Reid; Priyen Shah; Ortensia Vito; Elizabeth Whittaker; Clare Wilson; Rebecca Womersley

Recruitment team at Imperial College Healthcare NHS Trust, London (alphabetical order)2

Amina Abdulla; Sarah Darnell; Sobia Mustafa

Engineering Team

Pantelis Georgiou3 (engineering lead); Jesus-Rodriguez Manzano4; Nicolas Moser3; Ivana Pennisi1 1Section of Paediatric Infectious Disease, Imperial College London, Norfolk Place, London W2 1PG, UK

2Children's Clinical Research Unit, St Mary's Hospital, Praed Street, London W2 1NY, UK

3 Imperial College London, Department of Electrical and Electronic Engineering, South Kensington Campus, London, SW7 2AZ, UK

4 Imperial College London, Department of Infectious Disease, Section of Adult Infectious Disease, Hammersmith Campus, London, W12 ONN, UK

UK Non-Consortium Clinical Recruiting Sites

Evelina London Children's Hospital, Guy's and St Thomas' NHS Foundation Trust; King's College London [combined]

Michael Carter1,2 (principal investigator); Shane Tibby1,2 (co-investigator)

Recruitment team (alphabetical order): Jonathan Cohen1; Francesca Davis1; Julia Kenny1; Paul Wellman1; Marie White1

Laboratory team (alphabetical order): Matthew Fish3; Aislinn Jennings4; Manu Shankar-Hari3,4

1 Evelina London Children's Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK

2 Department of Women and Children's Health, School of Life Course Sciences, King's College London, UK

3 Department of Infectious Diseases, School of Immunology and Microbial Sciences, King's College London, London, UK

4 Department of Intensive Care Medicine, Guy's and St Thomas' NHS Foundation Trust, London, UK

University Hospitals Sussex

Katy Fidler1 (principal investigator); Dan Agranoff2 (co-investigator)

Recruitment team; Vivien Richmond1,3, Mathhew Seal2

1 Royal Alexandra Children's Hospital, University Hospitals Sussex, Brighton, UK

2 Dept of Infectious Diseases, University Hospitals Sussex, Brighton, UK

3 Research Nurse team, University Hospitals Sussex, Brighton, UK

University Hospital Southampton NHS Foundation Trust

Saul Faust1 (principal investigator); Dan Owen1 (co-investigator);

Recruitment team; Ruth Ensom2; Sarah McKay2; Diana Mondo3, Mariya Shaji3; Rachel Schranz3 (alphabetical order)

1 NIHR Southampton Clinical Research Facility, University Hospital Southampton NHS Foundation Trust and University of Southampton, UK

2 NIHR Southampton Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, UK 3 Department of R&D, University Hospital Southampton NHS Foundation Trust, UK

Barts Health NHS Trust

Prita Rughnani1, 2, 3 (principal investigator 2020-2021); Amutha Anpananthar1, 2, 3 (principal investigator 2021-to date); Susan Liebeschuetz2 (co-investigator), Anna Riddell1 (co-investigator) Recruitment team; Nosheen Khalid1, 3,Ivone Lancoma Malcolm, Teresa Simagan3 (alphabetical order)

1 Royal London Hospital, Whitechapel Rd, London E1 1FR, UK

2 Newham University Hospital, Glen Rd, London E13 8SL, UK

3 Whipps Cross University Hospital, Whipps Cross Road, London, E11 1NR, UK

Great Ormond Street Hospital for Children NHS Foundation Trust

Mark Peters1,2 (principal investigator); Alasdair Bamford1,2 (co-investigator)

Recruitment team; Lauran O'Neill1

1 Great Ormond Street Hospital, London, WC1N 3JH, UK

2 UCL Great Ormond St Institute of Child Health, WC1N 1EH, UK

Cambridge University Hospitals NHS Foundation Trust

Nazima Pathan1,2 (principal investigator)

Recruitment team; Esther Daubney1, Deborah White1 (alphabetical order)

1Addenbrooke's Hospital, Hills Road, Cambridge CB2 0QQ, UK

2Department of Paediatrics, University of Cambridge, Cambridge CB2 0QQ, UK

University College London Hospitals NHS Foundation Trust Melissa Heightman1 (principal investigator); Sarah Eisen1 (co-investigator)

Recruitment team; Terry Segal1, Lucy Wellings1 (alphabetical order)

1 University College London Hospital, Euston Road, London NW1 2BU, UK

St George's University Hospitals NHS Foundation Trust

Simon B Drysdale1 (principal investigator)

Recruitment team; Nicole Branch1, Lisa Hamzah1, Heather Jarman1 (alphabetical order)

1 St George's Hospital, Blackshaw Road, London SW17 0QT, UK

Lewisham and Greenwich NHS Trust

Maggie Nyirenda1, 2,(principal investigator)

Recruitment team Lisa Capozzi1, Emma Gardiner1 (alphabetical order)

1University Hospital Lewisham, London SE13 6LH, UK

2 Queen Elizabeth Hospital Greenwich, London SE18 4QH, UK

Liverpool University Hospitals NHS Foundation Trust Robert Moots1 (principal investigator); Magda Nasher2 (principal investigator) Recruitment team; Anita Hanson2; Michelle Linforth1 1 Aintree University Hospital, Lower Lane, Liverpool L9 7AL, UK 2 Royal Liverpool Hospital, Prescot St, Liverpool L7 8XP, UK

Leeds Teaching Hospitals NHS Trust Sean O'Riordan1 (principal investigator) Recruitment team; Donna Ellis1 1Leeds Children's Hospital, Leeds LS1 3EX, UK

King's College Hospital NHS Foundation Trust

Akash Deep1 (principal investigator)

Recruitment team; Ivan Caro1

1 Kings College Hospital, Denmark Hill, London SE5 9RS, UK

Sheffield Children's NHS Foundation Trust

Fiona Shackley 1 (principal investigator);

Recruitment team; Arianna Bellini,1 Stuart Gormley1 (alphabetical order)

1Sheffield Children's Hospital, Broomhall, Sheffield S10 2TH, UK

University Hospitals of Leicester NHS Foundation Trust

Samira Neshat1 (principal investigator)

1Leicester General Hospital, Leicester LE1 5WW, UK

Birmingham Women's and Children's Hospital NHS Foundation Trust
Barnaby J Scholefield1 (principal investigator)
Recruitment team; Ceri Robbins1, Helen Winmill1 (alphabetical order)
1 Birmingham Children's Hospital, Steelhouse Lane, Birmingham B4 6NH, UK
PARTNER: University of Oxford (UK)

Children's Hospital, John Radcliffe Hospital, Oxford

Principal Investigator

Stéphane C. Paulus1,2,3

Co-Principal Investigator

Andrew J. Pollard1,2,3,4

Co-investigators

Mark Anthony1 (neonates)

Recruitment team

Sarah Hopton1, Danielle Miller1, Zoe Oliver1, Sally Beer1, Bryony Ward1

1John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK

2Department of Paediatrics, University of Oxford, UK

3Oxford Vaccine Group, University of Oxford, UK

4NIHR Oxford Biomedical Research Centre, Oxford, UK

University of Oxford, Nepal Site

Principal Investigator

Shrijana Shrestha1

Co-Principal Investigator

Andrew J Pollard2,3

Nepal Research Team

Meeru Gurung1

Puja Amatya1

Bhishma Pokhrel1

Sanjeev Man Bijukchhe1

Oxford Research Team

Tim Lubinda2

Sarah Kelly2

Peter O'Reilly2

1Paediatric Research Unit, Patan Academy of Health Sciences, Kathmandu, Nepal.

2Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom.

3NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom.

PARTNER: SERGAS (Spain)

Principal Investigators

Federico Martinón-Torres1

Antonio Salas1,2

GENVIP RESEARCH GROUP (in alphabetical order):

Fernando Álvez González1, Xabier Bello1,2, Mirian Ben García1, Sandra Carnota1, Miriam Cebey-López1, María José Curras-Tuala1,2, Carlos Durán Suárez1, Luisa García Vicente1, Alberto Gómez-Carballa1,2, Jose Gómez Rial1, Pilar Leboráns Iglesias1, Federico Martinón-Torres1, Nazareth Martinón-Torres1, José María Martinón Sánchez1, Belén Mosquera Pérez1, Jacobo Pardo-Seco1,2, Lidia Piñeiro Rodríguez1, Sara Pischedda1,2, Sara Rey Vázquez1, Irene Rivero Calle1, Carmen Rodríguez-Tenreiro1, Lorenzo Redondo-Collazo1, Miguel Sadiki Ora1, Antonio Salas1,2, Sonia Serén Fernández1, Cristina Serén Trasorras1, Marisol Vilas Iglesias1.

1 Translational Pediatrics and Infectious Diseases, Pediatrics Department, Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain, and GENVIP Research Group (www.genvip.org), Instituto de Investigación Sanitaria de Santiago, Universidad de Santiago de Compostela, Galicia, Spain.

2 Unidade de Xenética, Departamento de Anatomía Patolóxica e Ciencias Forenses, Instituto de Ciencias Forenses, Facultade de Medicina, Universidade de Santiago de Compostela, and GenPop Research Group, Instituto de Investigaciones Sanitarias (IDIS), Hospital Clínico Universitario de Santiago, Galicia, Spain

3 Fundación Pública Galega de Medicina Xenómica, Servizo Galego de Saúde (SERGAS), Instituto de Investigaciones Sanitarias (IDIS), and Grupo de Medicina Xenómica, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Universidade de Santiago de Compostela (USC), Santiago de Compostela, Spain

PARTNER: Liverpool (UK)

Principal Investigators

Enitan D Carrol1,2,

Research Group (in alphabetical order):

Elizabeth Cocklin1, Aakash Khanijau1, Rebecca Lenihan1, Nadia Lewis-Burke1 Karen Newall4, Sam Romaine1, 1 Department of Clinical Infection, Microbiology and Immunology, University of Liverpool Institute of Infection, Veterinary and Ecological Sciences, Liverpool, England 2 Alder Hey Children's Hospital, Department of Infectious Diseases, Eaton Road, Liverpool, L12 2AP 3 4Alder Hey Children's Hospital, Clinical Research Business Unit, Eaton Road, Liverpool, L12 2AP

PARTNER: NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS (Greece)

Principal Investigator: Maria Tsolia1

Co-Investigator: Irini Eleftheriou1

PID Unit: Nikos Spyridis1, Maria Tambouratzi1

Pediatric Rheumatology Unit: Despoina Maritsi1

Lab: Antonios Marmarinos1, Marietta Xagorari1

Recruitment teams:

Adult COVID19- Infectious Diseases: Lourida Panagiota, Pefanis Aggelos2

Adult COVID19: Akinosoglou Karolina, Gogos Charalambos, Maragos Markos3

Adult Inflammatory Diseases-Oncology: Voulgarelis Michalis , Stergiou Ioanna4

12nd Department of Pediatrics, National and Kapodistrian University of Athens (NKUA), Children's Hospital "P, and A. Kyriakou", Athens, Greece

21st Department of Infectious Diseases, General Hospital "Sotiria"

3Pathology Department, University of Patras, General Hospital "Panagia i Voithia"

4Pathophysiology Department, Medical Faculty, National and Kapodistrian University of Athens (NKUA), General Hospital "Laiko"

Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University (UK) combined

Principal Investigator:

Marieke Emonts 1,2,3 (all activities)

Co-investigators

Emma Lim2,3,6 (all activities)

John Isaacs1 (adult inflammatory)

Recruitment team (alphabetical), datamanagers, and GNCH Research unit:

Kathryn Bell4, Stephen Crulley4, Daniel Fabian4, Evelyn Thomson4, Diane Wallia4, Caroline Miller4, Ashley Bell4

PhD Students/medical staff DIAMONDS

Fabian J.S. van der Velden1,2 (all activities), Geoff Shenton7 (oncology), Ashley Price8,9 (Adult COVID)

Students

Owen Treloar 1,2 (quality control, data management and analysis)

Daisy Thomas1,2 (recruitment)

Author Affiliations:

1 Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne UK

2Great North Children's Hospital, Paediatric Immunology, Infectious Diseases & Allergy, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom.

3NIHR Newcastle Biomedical Research Centre based at Newcastle upon Tyne Hospitals NHS Trust and Newcastle University, Westgate Rd, Newcastle upon Tyne NE4 5PL, United Kingdom

4Great North Children's Hospital, Research Unit, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom.

6Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK

7Great North Children's Hospital, Paediatric Oncology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom.

8Department of Infection & Tropical Medicine, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom

9NIHR Newcastle In Vitro Diagnostics Co-operative (Newcastle MIC), Newcastle upon Tyne, United Kingdom.

Servicio Madrileño de Salud (SERMAS) - Fundación Biomédica del Hospital Universitario 12 de Octubre (FIB-H12O) (Spain)

Principal Investigators

Pablo Rojo1 3

Cristina Epalza 1,2

SERMAS/FIB-H120 team:

Serena Villaverde 1,, Sonia Márquez2, Manuel Gijón 2, Fátima Machín2, Laura Cabello2, Irene Hernández2, Lourdes Gutiérrez2, Ángela Manzanares 1

Author Affiliations:

1 Servicio Madrileño de Salud (SERMAS), Pediatric Infectious Diseases Unit, Department of Pediatrics, Hospital Universitario 12 de Octubre, Madrid, Spain

2Fundación Biomédica del Hospital Universitario 12 de Octubre (FIB-H12O), Unidad Pediátrica de Investigación y Ensayos Clínicos (UPIC), Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (i+12), Madrid, Spain.

3 Universidad Complutense de Madrid, Faculty of Medicine, Department of Pediatrics, Madrid, Spain.

Amsterdam University Medical Center (Amsterdam UMC), University of Amsterdam

Principal Investigator:

T.W. (Taco) Kuijpers MD PhD 1,2 (all activities)

Co-investigators

M. (Martijn) van de Kuip MD PhD 1 (infectious disease)

A.M. (Marceline) van Furth MD PhD 1 (infectious disease)

J.M. (Merlijn) van den Berg MD PhD 1 (inflammatory disease)

Hospital Team (all activities):

Giske Biesbroek MD PhD 1, Floris Verkuil MD (PhD student) 1, Carlijn (C.W.) van der Zee MD (start 1/8/2022, PhD student) 1

Recruitment:

Dasja Pajkrt MD PhD 1, Michael Boele van Hensbroek MD PhD 1, Dieneke Schonenberg MD 1, Mariken Gruppen MD 1, Sietse Nagelkerke MD PhD 1,2, medical students

Laboratory Team:

Machiel H Jansen 1, Ines Goetschalckx (PhD student) 2

Author Affiliations:

1 Amsterdam UMC, Emma Children's Hospital, Dept of Pediatric Immunology, Rheumatology and Infectious Disease, University of Amsterdam, The Netherlands

2 Sanquin, Dept of Molecular Hematology, University Medical Center, Amsterdam, The Netherlands

Bambino Gesù Children's Hospital (Rome-Italy)

Principal Investigator

Lorenza Romani 1

Maia De Luca 1

Recruitment Team

Sara Chiurchiù 1

Martina Di Giuseppe 1

Affiliation

1 Infectious Disease Unit, Academic Department of Pediatrics, Bambino Gesù Children's Hospital, IRCCS, Rome 00165, Italy

ERASMUS MC-Sophia Children's Hospital

Principal Investigator

Clementien L. Vermont²

Research group

Henriëtte A. Moll¹, Dorine M. Borensztajn¹, Nienke N. Hagedoorn, Chantal Tan ¹, Joany Zachariasse ¹, Medical students ¹

Additional investigator

W Dik 3

¹ Erasmus MC-Sophia Children's Hospital, Department of General Paediatrics, Rotterdam, the Netherlands

² Erasmus MC-Sophia Children's Hospital, Department of Paediatric Infectious Diseases & Immunology, Rotterdam, the Netherlands

3 Erasmus MC, Department of immunology, Rotterdam, the Netherlands

TAIWAN

Ching-Fen (Kitty), Shen

Division of Infectious Disease, Department of Pediatrics, National Cheng Kung University

Tainan, Taiwan

Riga Stradins University (Riga, Latvia)

Principal Investigator:

Dace Zavadska 1,2 (all activities)

Co-investigators

Sniedze Laivacuma 1,3 (adult cohorts)

Recruitment team:

Aleksandra Rudzate 1,2, Diana Stoldere 1,2, Arta Barzdina 1,2, Elza Barzdina 1,2, Sniedze Laivacuma1,3, Monta Madelane 1,3

Laboratory

Dagne Gravele 2, Dace Svile2

Author Affiliations:

1 Riga Stradins University, Riga, Latvia

2 Children clinical university hospital, Riga, Latvia

3 Riga East clinical university hospital, Riga, Latvia

Assistance Publique - Hôpitaux de Paris

Principal Investigator:

Romain Basmaci 1,2

Co-investigator:

Noémie Lachaume 1

Recruitment team:

Pauline Bories 1, Raja Ben Tkhayat 1, Laura Chériaux 1, Juraté Davoust 1, Kim-Thanh Ong 1, Marie Cotillon 1, Thibault de Groc 1, Sébastien Le 1, Nathalie Vergnault 1, Hélène Sée 1, Laure Cohen 1, Alice de Tugny 1, Nevena Danekova 1

Author Affiliations:

1 Service de Pédiatrie-Urgences, AP-HP, Hôpital Louis-Mourier, F-92700 Colombes, France

² Université Paris Cité, Inserm, IAME, F-75018 Paris, France

BioMérieux

Principal Investigator:

Marine Mommert-Tripon

Co-investigator:

Karen Brengel-Pesce

Author Affiliations:

bioMérieux - Open Innovation & Partnerships Department, Lyon, France

University Medical Centre Ljubljana, Slovenia

Principal Investigator: Marko Pokorn 1,2,3

Co-Investigator: Mojca Kolnik2

Research Group (in alphabetical order):

Tadej Avčin2,3, Tanja Avramoska2, Natalija Bahovec1, Petra Bogovič1, Lidija Kitanovski2,3, Mirijam Nahtigal1, Lea Papst1, Tina Plankar Srovin1, Franc Strle1,2, Anja Srpčič2, Katarina Vincek1.

Affiliations:

1. Department of Infectious diseases, University Medical Centre Ljubljana, Slovenia

- 2. University Children's Hospital, University Medical Centre Ljubljana, Slovenia
- 3. Faculty of Medicine, University of Ljubljana, Slovenia
- 4. Centre for Clinical research, University Medical Centre Ljubljana

University Medical Center Utrecht, Utrecht, The Netherlands

Principal Investigator

Michiel van der Flier1,5 (Pediatric Infectious Diseases and Immunology)

Co-investigators

Wim J.E. Tissing5 (Pediatric Oncology)

Roelie M. Wösten-van Asperen2 (Pediatric Intensive Care Unit)

Sebastiaan J Vastert3 (Pediatric Rheumatology)

Daniel C Vijlbrief4 (Pediatric Neonatal Intensive Care)

Louis J. Bont1,5 (Pediatric Infectious Diseases and Immunology)

Tom F.W. Wolfs 1,5 (Pediatric Infectious Diseases and Immunology)

PhD student

Coco R. Beudeker1,5 (Pediatric Infectious Diseases and Immunology)

Affiliations:

 Pediatric Infectious Diseases and Immunology, 2. Pediatric Intensive Care Unit 3. Pediatric Rheumatology 4. Pediatric Neonatal Intensive Care, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, The Netherlands

5. Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands

PARTNER: University of Bern, Inselspital, Bern University Hospital, University of Bern (Switzerland)

Principal Investigators (alphabetical)

Philipp Agyeman1

Luregn Schlapbach2,3

Co-Investigator

Christoph Aebi1

Recruitment team

Mariama Usman1, Stefanie Schlüchter1, Verena Wyss1, Nina Schöbi1, Elisa Zimmermann2 PhD, Marion Meier2, Kathrin Weber2

Department of Pediatrics, Inselspital, Bern University Hospital, University of Bern, Switzerland
 Department of Intensive Care and Neonatology, and Children's Research Center, University
 Children's Hospital Zurich, Zurich, Switzerland

3 Child Health Research Centre, The University of Queensland, Brisbane, Australia

Swiss Pediatric Sepsis Study group

Philipp Agyeman, MD 1, Luregn J Schlapbach, MD, FCICM 2,3, Eric Giannoni, MD 4,5, Martin Stocker, MD 6, Klara M Posfay-Barbe, MD 7, Ulrich Heininger, MD 8, Sara Bernhard-Stirnemann, MD 9, Anita Niederer-Loher, MD 10, Christian Kahlert, MD 10, Giancarlo Natalucci, MD 11, Christa Relly, MD 12, Thomas Riedel, MD 13, Christoph Aebi, MD 1, Christoph Berger, MD 12

Affiliations:

1 Department of Pediatrics, Inselspital, Bern University Hospital, University of Bern, Switzerland

2 Department of Intensive Care and Neonatology, and Children's Research Center, University Children's Hospital Zurich, Zurich, Switzerland

3 Child Health Research Centre, The University of Queensland, Brisbane, Australia

4 Clinic of Neonatology, Department Mother-Woman-Child, Lausanne University Hospital and University of Lausanne, Switzerland

5 Infectious Diseases Service, Department of Medicine, Lausanne University Hospital and University of Lausanne, Switzerland

6 Department of Pediatrics, Children's Hospital Lucerne, Lucerne, Switzerland

7 Pediatric Infectious Diseases Unit, Children's Hospital of Geneva, University Hospitals of Geneva, Geneva, Switzerland

8 Infectious Diseases and Vaccinology, University of Basel Children's Hospital, Basel, Switzerland

9 Children's Hospital Aarau, Aarau, Switzerland

10 Division of Infectious Diseases and Hospital Epidemiology, Children's Hospital of Eastern Switzerland St. Gallen, St. Gallen, Switzerland

11 Department of Neonatology, University Hospital Zurich, Zurich, Switzerland

12 Division of Infectious Diseases and Hospital Epidemiology, and Children's Research Center, University Children's Hospital Zurich, Switzerland

13 Children's Hospital Chur, Chur, Switzerland

Micropathology Ltd (UK)

Micropathology Ltd, The Venture Center, University of Warwick Science Park, Sir William Lyons Road, Coventry, CV4 7EZ

Principle Investigator; Prof Colin Fink

Co Investigators: Marie Voice, Leo Calvo-Bado, Michael Steele, Jennifer Holden

Research group: Benjamin Evans, Jake Stevens, Peter Matthews, Kyle Billing

Medical University of Graz, Austria (MUG)

Principal Investigator: Werner Zenz1 (all activities) Co-investigators (in alphabetical order): Alexander Binder1 (grant application) Benno Kohlmaier1 (study design, recruitment) Daniela S. Kohlfürst1 (study design) Nina A. Schweintzger1 (all activities) Christoph Zurl1 (study design, recruitment)

Recruitment team, data managers, laboratory work (in alphabetical order):

Susanne Hösele1, Manuel Leitner1, Lena Pölz1, Alexandra Rusu1, Glorija Rajic1, Bianca Stoiser1, Martina Strempfl1, Manfred G. Sagmeister1

Clinical recruitment partners (in alphabetical order):

Sebastian Bauchinger1, Martin Benesch3, Astrid Ceolotto1, Ernst Eber2, Siegfried Gallistl1, Harald Haidl1, Almuthe Hauer1, Christa Hude1, Andreas Kapper7, Markus Keldorfer5, Sabine Löffler5, Tobias Niedrist6, Heidemarie Pilch5, Andreas Pfleger2, Klaus Pfurtscheller4, Siegfried Rödl4, Andrea Skrabl-Baumgartner1, Volker Strenger3, Elmar Wallner7

Author Affiliations:

 Department of Pediatrics and Adolescent Medicine, Division of General Pediatrics, Medical University of Graz, Graz, Austria
 2Department of Pediatric Pulmonology, Medical University of Graz, Graz, Austria

3Department of Pediatric Hematooncology, Medical University of Graz, Graz, Austria

4Paediatric Intensive Care Unit, Medical University of Graz, Graz, Austria

5University Clinic of Pediatrics and Adolescent Medicine Graz, Medical University Graz, Graz, Austria

6Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University Graz, Graz, Austria

7Department of Internal Medicine, State Hospital Graz II, Location West, Graz, Austria

SkylineDX

Principle investigator: Dennie Tempel 1

Co-investigators: Danielle van Keulen1, Annelieke M Strijbosch 1,

Author affiliations:

1 SkylineDx, Rotterdam, The Netherlands

Project partner BBMRI-ERIC

Maike K. Tauchert

Author affiliation:

Biobanking and BioMolecular Resources Research Infrastructure - European Research Infrastructure Consortium (BBMRI-ERIC), Neue Stiftingtalstrasse 2/B/6, 8010, Graz, Austria

LMU Munich Partner (Germany)

Principal Investigator:

Ulrich von Both1,2 MD, FRCPCH (all activities)

Research group:

Laura Kolberg¹ MSc (all activities)

Patricia Schmied¹ (Study physician), Irene Alba-Alejandre3 MD (Study physician)

Clinical recruitment partners (in alphabetical order):

Katharina Danhauser, MD6, Nikolaus Haas, MD11, Florian Hoffmann, MD10, Matthias Griese, MD7, Tobias Feuchtinger, MD5, Sabrina Juranek, MD4, Matthias Kappler, MD7, Eberhard Lurz, MD8, Esther Maier, MD4, Karl Reiter, MD10, Carola Schoen, MD10, Sebastian Schroepf, MD9

Author Affiliations:

¹ Division of Pediatric Infectious Diseases, Department of Pediatrics, Dr. von Hauner Children's Hospital, University Hospital, LMU Munich, Munich, Germany

2 German Center for Infection Research (DZIF), Partner Site Munich, Munich, Germany

3 Department of Gynecology and Obstetrics, University Hospital, LMU Munich, Munich, Germany

4 Division of General Pediatrics, Department of Pediatrics, Dr. von Hauner Children's Hospital, University Hospital, LMU Munich, Munich, Germany

5 Division of Pediatric Haematology & Oncology, Department of Pediatrics, Dr. von Hauner Children's Hospital, University Hospital, LMU Munich, Munich, Germany

6 Division of Pediatric Rheumatology, Department of Pediatrics, Dr. von Hauner Children's Hospital, University Hospital, LMU Munich, Munich, Germany

7 Division of Pediatric Pulmonology, Department of Pediatrics, Dr. von Hauner Children's Hospital, University Hospital, LMU Munich, Munich, Germany

8 Division of Pediatric Gastroenterology, Department of Pediatrics, Dr. von Hauner Children's Hospital, University Hospital, LMU Munich, Munich, Germany

9 Neonatal Intensive Care Unit, Department of Pediatrics, Dr. von Hauner Children's Hospital, University Hospital, LMU Munich, Munich, Germany

10 Paediatric Intensive Care Unit, Department of Pediatrics, Dr. von Hauner Children's Hospital, University Hospital, LMU Munich, Munich, Germany

11 Department of Pediatric Cardiology and Pediatric Intensive Care, University Hospital, LMU Munich, Germany

London School of Hygiene and Tropical Medicine (LSHTM)

Principal Investigator: Shunmay Yeung 1,2,3

Research group:

Manuel Dewez1 David Bath3, Elizabeth Fitchett1, Fiona Cresswell1

1. Clinical Research Department, Faculty of Infectious and Tropical Disease, London School of

Hygiene and Tropical Medicine, London

2. Department of Paediatrics, St. Mary's Imperial College Hospital, London

3. Department of Global Health and Development, Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London